Revenue Breakdown
Composition ()
No data
Revenue Streams
Neurocrine Biosciences Inc (NBIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is INGREZZA, accounting for 86.4% of total sales, equivalent to $686.60M. Other significant revenue streams include CRENESSITY and Other. Understanding this composition is critical for investors evaluating how NBIX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Neurocrine Biosciences Inc maintains a gross margin of 97.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28.29%, while the net margin is 19.08%. These profitability ratios, combined with a Return on Equity (ROE) of 16.38%, provide a clear picture of how effectively NBIX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NBIX competes directly with industry leaders such as ELAN and BBIO. With a market capitalization of $13.29B, it holds a leading position in the sector. When comparing efficiency, NBIX's gross margin of 97.82% stands against ELAN's 39.34% and BBIO's 94.74%. Such benchmarking helps identify whether Neurocrine Biosciences Inc is trading at a premium or discount relative to its financial performance.
